


In the Claims:

1. (Currently Amended) A compounds having the structure of Formula I



FORMULA - I

its and their pharmaceutically acceptable salts, ~~amides~~, enantiomers, diastereomers, N-oxides, ~~prodrugs, metabolites~~ or their polymorphs, wherein A is a straight or branched C₁-C₄ alkyl chain; R is cinnamyl, benzyl, substituted benzyl, ~~phenyl~~, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of ~~halogen~~, hydroxy, C₁-C₆-alkyl, C₁-C₆-alkoxy, ~~trifluoromethyl~~, nitro, ^{and} trifluoroalkoxy group, or *R, S* (dihalodiphenyl) methyl.

2. Cancelled

3. (Currently Amended) ~~The Compounds according to claim 1~~ selected from the group consisting of:


- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 01);
- 2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 02);
- 2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 03).

- Q1
- 2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 04);
 - 2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 05);
 - 2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 06);
 - 2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 07);
 - 2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 08);
 - 2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 09);
 - 2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 10);
 - 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 11);
 - 2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 12);
 - ~~2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 13);~~
 - 2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 14);
 - 2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 15);
 - 2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 16);
 - 2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 17);
 - 2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 18);

- a'
- 2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 19);
 - 2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 20);
 - 2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 21);
 - 2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 22);
 - 2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 23);
 - 2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 24);
 - 2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 25);
 - 2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 26);
 - 2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 27);
 - 2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 28);
 - 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 29);
 - 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 30);
 - 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 31).

4. (Cancelled)

5. (Currently Amended) A method for treating benign prostatic hyperplasia in a mammal comprising administering to said mammal a compound having the structure of Formula I



FORMULA - I


or its pharmaceutically acceptable salts, ~~amides~~, enantiomers, diastereomers, N-oxides, ~~prodrugs~~, ~~metabolites~~ or their polymorphs, wherein A is a straight or branched C₁-C₄ alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted with the substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group, or (dihalodiphenyl) methyl.

6. (Currently Amended) A pharmaceutical composition comprising ~~the~~ a compound of claims 1 or 3 and a pharmaceutical acceptable carrier.

7. (Cancelled)


8. (Currently Amended) A method for treating benign prostatic hyperplasia in a mammal comprising ~~the step of~~ administering to the said mammal, the pharmaceutical composition according to claim 6.

9. (Currently Amended) A process for preparing a compounds of Formula I




FORMULA - I

a' or its and their pharmaceutically acceptable salts, ~~amides~~, enantiomers, diastereomers, N-oxides, ~~prodrugs, metabolites~~ or their polymorphs, wherein A is a straight or branched C₁-C₄ alkyl chain; R is cinnamyl, benzyl, substituted benzyl, ~~phenyl~~, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of ~~halogen~~, hydroxy, ~~C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl~~, nitro, trifluoroalkoxy group, or (dihalodiphenyl) methyl, ~~which comprises~~ comprising reacting ~~a compound~~ cis 1,2,3,6-tetrahydrophthalic anhydride of Formula II



FORMULA II


with ~~piperazine derivatives~~ 1-amino-4-substituted piperazinyl alkane of Formula III,



FORMULA III

~~as shown in Scheme I~~ wherein A and R are ~~the same~~ as defined above, in the presence of a solvent selected from the group consisting of pyridine, n-butanol, benzene and xylene.

10. (Currently Amended) A process for preparing a compounds of Formula I




FORMULA - I

or its and their pharmaceutically acceptable salts, ~~amides~~, enantiomers, diastereomers, N-oxides, ~~prodrugs, metabolites~~ or their polymorphs, wherein A is a straight or branched C₁-C₄ alkyl chain;


a1
R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C₁-C₆ alkyl, C₁-C₆ alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group or (dihalodiphenyl) methyl, ~~which comprises~~ comprising reacting

1-(ω-haloalkyl)cis-3a,4,7,7a-tetrahydrophthalimide of Formula IV, wherein A is ~~the same~~ as



FORMULA IV

defined above, with ~~a compound~~ 1-substituted piperazine of Formula V,



FORMULA V

wherein R is ~~the same~~ as defined above, ~~as shown in Scheme II.~~
